Global analysis for downstream of NACC1 gene expression by next generation of sequencing method.
Project/Area Number |
25860964
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Iwate Medical University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | NACC1 / 網羅的解析 / HDAC6 / YAP/TAZ / HADC / SOX2 / NANOG / SUMOlyation / 皮膚病理 / 多能性 / 転写因子 |
Outline of Final Research Achievements |
There has been increasing interest in the cancer research field concerning the BTB/POZ (bric-a-brac tramtrack broad complex/ pox virus and Zn finger) family of proteins. NACC1 is a member of the BTB/POZ family and a transcriptional repressor associated with tumor cell growth, survival and chemosensitivity. To clarify other functions of NACC1 associated with tumor biology, we performed global analysis using next generation of sequencing method,. NACC1 occupied the promoters accompanying with SETDB1. NACC1 and cytoplasmic HDAC6 were demonstrated by coimmunoprecipitation, pull-down, and yeast two-hybrid assays. NACC1/NANOG/HDAC6/SETDB1 complex regulated p16 expression through epigenetic mechanisms. The study presented the role of NACC1 gene in malignant tumor behaviors.
|
Report
(4 results)
Research Products
(6 results)
-
-
-
-
[Journal Article] A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.2014
Author(s)
Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A, Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka T, Masuda T, Maesawa C.
-
Journal Title
J Invest Dermatol.
Volume: 134(2)
Issue: 2
Pages: 553-556
DOI
Related Report
Peer Reviewed
-
-